Investing Profile

Andrew Levin

VC
Photo of Andrew Levin, Managing Partner at RA Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
RA Capital Managing Partner
18
CompanyStageDateRound SizeTotal Raised
Aktis Oncology
Series BSep 2024$180M
$330M
Co-investors: Jason Ruth (5am Ventures), Todd Foley (MPM Capital)
Superluminal Medicines
Series ASep 2024$120M
SeedAug 2023$33M
$150M
Co-investors: Dylan Morris (Insight Partners)
Navigator Medicines
Series AAug 2024$100M
$100M
Co-investors: Wouter Joustra (Forbion)
Eliem Therapeutics
Post Ipo EquityApr 2024$120M
Series BMay 2021$60M
Series AMar 2021$80M
$260M
Co-investors: Liam Ratcliffe (Access Biotechnology), Ohad Hammer (Pontifax Venture Capital)
Lusaris Therapeutics
Series ANov 2022$60M
$60M
Metagenomi
Series BJan 2022$180M
Series ANov 2020$75M
$280M
Co-investors: Sebastian Bernales (Humboldt Fund), Victor Wang (HOF Capital), Kyle Kurpinski (Tencent Holdings), Jeremy Yap
Expansion Therapeutics
Series BSep 2021$80M
Series AJan 2018$55M
$140M
Co-investors: Scott Rocklage (5am Ventures), Beth Seidenberg (Westlake Village BioPartners)
Delix Therapeutics
Series ASep 2021$70M
$70M
Co-investors: Ken Belotsky (Negev Capital), Vasudev Bailey (Artis Ventures (AV)), Matias Serebrinsky (PsyMed Ventures)